| Date | Title | | | 03/16/10 | Molecular Insight Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial and Operational Results| CAMBRIDGE, MA, Mar 16, 2010 (MARKETWIRE via COMTEX) -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, today announced financial and operational results for the fourth quarter and year-ended December 31, 2009.
At December 31, 2009, the Company had approximately $64.0 million in cash, cash equivalents, and short-term investments, 25,268,327 shares of common s... |
|  | | 03/16/10 | Molecular Insight Pharmaceuticals, Inc. to Report Fourth Quarter and
Year-End 2009 Financial and Operational Results Today| CAMBRIDGE, MA, Mar 16, 2010 (MARKETWIRE via COMTEX) -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced it
will report fourth quarter and year-end 2009 financial results today,
March 16, 2010.
Following the release of the results this afternoon, the Company will
host a conference call at 4:30 p.m., Eastern Time, during which
Molecular Insight management will discuss financial and operating
highlights.
Conference Call Details
To access the call, dial 888.679.8033 (or 61... |
| | | 03/15/10 | Molecular Insight Pharmaceuticals Receives NASDAQ Notification Letter| CAMBRIDGE, MA, Mar 15, 2010 (MARKETWIRE via COMTEX) -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, announced today the Company received a letter from The NASDAQ Stock Market on March 9, 2010 notifying the Company that for the 30 consecutive business days preceding the date of the letter the Company's listed securities did not meet the minimum $50 million M... |
| | | 01/27/10 | Molecular Insight Announces Updates to Board of Directors| CAMBRIDGE, MA, Jan 27, 2010 (MARKETWIRE via COMTEX) -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, announced that David R. Epstein and Yvonne Greenstreet, M.D., have resigned from its Board of Directors.
The resignations of Mr. Epstein and Dr. Greenstreet reflect significantly increased work commitments at their respective companies. Mr. Epstein recently... |
| |
|
Print Page | 
Email Page | 
RSS Feeds | 
Email Alerts | 
IR Contacts | 
Financial Tear Sheet